Patents by Inventor Talia Shekhter
Talia Shekhter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827687Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: February 3, 2022Date of Patent: November 28, 2023Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmilla Buzhansky
-
Publication number: 20230074255Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: April 8, 2022Publication date: March 9, 2023Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 11389544Abstract: The present invention provides nanoparticle conjugates incorporating the self-assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanospheres. The present invention further provides nanoparticles formed by supramolecular co-assembly of the conjugates with a diphenylalanine (FF) dipeptide or analog thereof, to generate bioactive self-assembled nanostructures.Type: GrantFiled: January 19, 2017Date of Patent: July 19, 2022Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Talia Shekhter Zehavi, Ehud Gazit, Mor Herman-Oron, Genady Kostenich, Arie Orenstein
-
Publication number: 20220162284Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: February 3, 2022Publication date: May 26, 2022Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmilla BUZHANSKY
-
Patent number: 11261230Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: June 28, 2020Date of Patent: March 1, 2022Assignees: RAMOT AT TEL AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20210170048Abstract: The present invention provides nanoparticle conjugates incorporating the self-assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanospheres. The present invention further provides nanoparticles formed by supramolecular co-assembly of the conjugates with a diphenylalanine (FF) dipeptide or analog thereof, to generate bioactive self-assembled nanostructures.Type: ApplicationFiled: January 19, 2017Publication date: June 10, 2021Inventors: Talia SHEKHTER ZEHAVI, Ehud GAZIT, Mor HERMAN-ORON, Genady KOSTENICH, Arie ORENSTEIN
-
Patent number: 10870842Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: March 18, 2019Date of Patent: December 22, 2020Assignee: PROTALIX LTD.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Publication number: 20200325203Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: June 28, 2020Publication date: October 15, 2020Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 10723780Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: March 19, 2019Date of Patent: July 28, 2020Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20190276513Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: March 19, 2019Publication date: September 12, 2019Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Publication number: 20190256832Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: March 18, 2019Publication date: August 22, 2019Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10280414Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: June 29, 2017Date of Patent: May 7, 2019Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10266579Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: September 10, 2015Date of Patent: April 23, 2019Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20180148703Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: June 29, 2017Publication date: May 31, 2018Applicant: Protalix Ltd.Inventors: Avidor SHULMAN, Ilya RUDERFER, Tehila BEN-MOSHE, Talia SHEKHTER, Yaniv AZULAY, Tali KIZHNER, Yoseph SHAALTIEL
-
Publication number: 20170298113Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: September 10, 2015Publication date: October 19, 2017Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 9708595Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: November 10, 2015Date of Patent: July 18, 2017Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben Moshe, Talia Shekhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Publication number: 20160053247Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: November 10, 2015Publication date: February 25, 2016Applicant: PROTALIX LTD.Inventors: Avidor SHULMAN, Ilya RUDERFER, Tehila BEN-MOSHE, Talia SHEKHTER, Yaniv AZULAY, Yoseph SHAALTIEL, Tali KIZHNER
-
Patent number: 9194011Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: March 2, 2011Date of Patent: November 24, 2015Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay